Total Funding
73
44
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2824445
HemoSense manufactures handheld blood coagulation monitoring systems for the management of warfarin medications.
Acquired by 
Inverness Medical
Gordon Sangster: CFOPast Role: Nexus Dx, CFO- Emmanuel Mpock: Team MemberPast Role: Farallon Capital Management, Team Member
About the Company
HemoSense manufactures handheld blood coagulation monitoring systems for the management of warfarin medications for patients and healthcare professionals.
It offers INRatio System that measures the patient's blood clotting time to ensure that patients with a propensity to form clots are maintained within the therapeutic range with the
proper dosage of oral anticoagulant therapy. The company offers its products through distributor partners.
HemoSense, Inc. was formerly known as CardioSense, Inc. and changed its name to HemoSense, Inc. in January 1998. It was founded in 1997 and is based in San Jose, California. As of November 6, 2007, HemoSense, Inc. operates as a subsidiary of Alere Inc.
